Beata Ambroziewicz: Patient Concerns About Biosimilars

Beata Ambroziewicz, president of the Polish Union of Patient Organizations and board member of the Polish Cancer Patient Coalition, discusses patients' concerns about biosimilars and the need for more education about switching.
March 29, 2019


Concerns are mainly focused on switching from original to biosimilar, not only in terms of safety, or whether this treatment is good for me, but more it comes from a lot of misleading information and not enough contact with doctors. We are not discussing enough the issue of switching. Patients are getting to know that they were switched after [the fact]. It causes a lot of questions: why is the process not transparent enough? We really focus on patient education, and we’re trying to prepare different materials that everyone can educate themselves when patients start biological treatment.


Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.